Background
Tralokinumab was recently approved for the treatment of moderate to severe AD and is the first selective IL-13 inhibitor that specifically neutralizes IL-13 with high affinity.
Objectives
To determine the real-life short-term effectiveness and safety of Tralokinumab treatment in AD patients with moderate to severe AD
Methods
A multicentre retrospective study was conducted including adult patients with moderate to severe AD who initiated Tralokinumab treatment from 1 April to 30 June 2022 in 16 spanish hospitals. Demographic and disease characteristics, severity and quality of life scales were collected at the baseline visit and at weeks 4 and 16.
Results
Eighty-five patients were included. Twenty-seven patients (31.8%) were non-naïve to advanced therapy (biological or JAK inhibitors). All included patients had severe disease with baseline EASI scores of 25.4 ± 8.1, DLQI 15.8 ± 5.4 and PP-NRS 8.1 ± 1.8. Sixty-five percent of the patients had an IGA of 4. At week 16, all scales improved significantly. The mean EASI decreased to 7.5 ± 6.9 (70.4% improvement), SCORAD improved 64.1% and PP-NRS, 57.1%. Also, 82.4%, 57.6% and 21.2% of the patients achieved EASI 50, 75 and 90, respectively. The percentage of EASI75 responders was significantly higher among naïve versus non-naïve patients (67.2% vs 40.7%). The safety profile was quite acceptable.
Conclusions
Patients, with a long history of disease and prior multidrug failure, showed a good response to Tralokinumab, confirming clinical trial results.
Case SynopsisCase 1 An 82-year-old woman was referred for a painful nodule on her left sole, which had gradually enlarged over the prior 6 months. She denied a history of trauma . On physical examination, she exhibited a unique well-defined, skin-colored nodule on her left sole (Figure 1A). Ultrasonography revealed a hypoechoic, well-circumscribed oval nodule measuring 21mm in maximum diameter. On color
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.